Global Health Intrinsic Value
MEDANTA Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹339.00 | ₹271.20 - ₹406.80 | -70.0% | EPS: ₹23.56, Sector P/E: 12x |
| Book Value Method | asset | ₹627.41 | ₹564.67 - ₹690.15 | -44.5% | Book Value/Share: ₹627.41, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹672.59 | ₹605.33 - ₹739.85 | -40.5% | Revenue/Share: ₹840.74, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹1140.99 | ₹1026.89 - ₹1255.09 | +1.0% | EBITDA: ₹1068.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹1569.63 | ₹1255.70 - ₹1883.56 | +38.9% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹339.00 | ₹305.10 - ₹372.90 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹339.00 | ₹305.10 - ₹372.90 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹1638.52 | ₹1474.67 - ₹1802.37 | +45.0% | ROE: 18.7%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹576.71 | ₹519.04 - ₹634.38 | -49.0% | EPS: ₹23.56, BVPS: ₹627.41 |
Want to compare with current market value? Check MEDANTA share price latest .
Valuation Comparison Chart
MEDANTA Intrinsic Value Analysis
What is the intrinsic value of MEDANTA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Global Health (MEDANTA) is ₹627.41 (median value). With the current market price of ₹1130.00, this represents a -44.5% variance from our estimated fair value.
The valuation range spans from ₹339.00 to ₹1638.52, indicating ₹339.00 - ₹1638.52.
Is MEDANTA undervalued or overvalued?
Based on our multi-method analysis, Global Health (MEDANTA) appears to be trading above calculated value by approximately 44.5%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 2.02 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.41 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 18.7% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 21.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.95x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Global Health
Additional stock information and data for MEDANTA
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹624 Cr | ₹264 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹612 Cr | ₹392 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹645 Cr | ₹474 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹311 Cr | ₹101 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹242 Cr | ₹123 Cr | Positive Free Cash Flow | 8/10 |